Prodotti competitors / Area Oncology
Ribociclib - Findings from the MAINTAIN study
Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treatment and Received Ribociclib After Previous CDK4/6 Inhibitor and Different Endocrine Therapy
the full article is availabel at ESMO Oncology News (Link)
Grazie per il tuo feedback!